OBESITY OR OVERWEIGHT TYPE II DIABETES
Embold | D7260C00015
Sponsor: AstraZeneca
This study is a Phase III randomized, double-blind, placebo controlled multi-center master protocol to evaluate the ffficacy and safety of Elecoglipron in participants with Obesity or Overweight and Type II Diabetes Mellitus.
SELENE 2 | D8750C00012
Sponsor: AstraZeneca
This study is a Phase III randomized, double-blind, placebo-controlled multi-center trial evaluating the efficacy and safety of AZD6234 in adults with Type II Diabetes Mellitus and Obesity or Overweight.
Interested in Learning More About Obesity or Diabetes Trials?
Submit your information and our team will follow up within 24–48 hours.
What Can I Expect if I Enroll?
If you are interested in learning more or enrolling, our staff will contact you within a few days.
There is no obligation, and your information will be kept confidential. Our staff will:
- Screen interested participants for eligibility in active clinical trials
- Determine whether you may qualify for participation
- Explain study details, including protocol, duration, and compensation (varies by study)
- Provide clear guidance on the study process from start to finish and answer any questions
- Communicate with your established physician, as appropriate, regarding your participation
- Patient enrollment and participation are voluntary and may be discontinued at any time
Patients enrolled in our clinical trials remain under the care of their established physician for routine healthcare.
Simply provide your contact information, and our staff will guide you through the next steps.